301363 (Meihao Medical) Analysis of Limit-Up Reasons, Market Sentiment, and Trend Forecast

301363 (Meihao Medical) hit the limit-up mainly driven by multiple catalysts for the Brain-Computer Interface (BCI) concept:

1. Industry Event Driver
   : On December 31, 2025, Elon Musk announced that Neuralink would mass-produce BCI devices in 2026 [3], triggering a global BCI concept boom;
2. Policy Support
   : On December 26, 2024, the National Medical Products Administration released the “Priority Approval Catalogue for High-End Medical Devices”, including implantable BCI devices [2];
3. Company Participation
   : On December 12, 2025, the company replied on an interactive platform that it is actively cooperating with downstream BCI customers to promote product commercialization [5].

On January 5, 2026, the company’s stock hit the limit-up (20% increase), closing at 28.86 yuan [4]; trading volume was 7.38 million shares, turnover was 2.13 billion yuan, and turnover rate was 1.98% [4]; net inflow of main funds was 615 million yuan, accounting for 28.87% of total trading volume [4].

The BCI concept sector strengthened overall, with over 20 stocks hitting limit-up [1][3]; institutions are optimistic about the company’s prospects—over the past 90 days, 12 institutions issued ratings, with 11 being Buy and 1 being Overweight [4].

1. Significant Sector Linkage Effect
   : Meihao Medical’s limit-up is not an isolated event but part of the overall surge in the BCI concept sector, reflecting the market’s high attention to the commercialization prospects of BCI technology;
2. High Institutional Recognition
   : Most institutions gave Buy ratings, indicating long-term optimism about the company’s layout potential in the BCI field;
3. Obvious Capital-Driven Characteristics
   : Large net inflows of main funds drove the stock to limit-up, with high short-term market enthusiasm.

1. Limited Contribution from BCI Business
   : Currently, the BCI business contributes little to the company’s revenue, and there is uncertainty about performance realization [5];
2. Short-Term Profit-Taking Pressure
   : The stock price has reached a 60-day high, and some profit-taking positions may cash out gains [4];
3. Need for Valuation Digestion
   : The current stock price (28.86 yuan) is higher than the average cost (23.15 yuan), and the market needs time to digest the gains [5].

As an important direction in the emerging medical field, BCI technology has favorable policy support and industry development expectations. If the company can continue to advance its BCI business layout, it is expected to benefit in the long term.

• Limit-Up Catalysts: Neuralink’s mass production plan, policy support, company’s BCI business layout;
• Market Performance: Closed at limit-up of 28.86 yuan, turnover of 2.13 billion yuan, net inflow of main funds of 615 million yuan;
• Market Sentiment: Active BCI sector, institutional ratings mostly Buy;
• Key Prices: Support level at 23.15 yuan (average cost), resistance level at 28.86 yuan (current closing price);
• Risks to Watch: Small contribution from BCI business, short-term profit-taking pressure